Researchers have reported the case of a 19-year-old man whose only symptom of hereditary angioedema (HAE) was abdominal pain. His diagnosis relied on laboratory tests, which revealed normal levels, but low activity, of the C1 inhibitor protein (C1-INH) — a telltale sign of HAE type 2. The man’s case…
Firazyr (icatibant injection) appears to be at least as safe and effective at controlling swelling attacks in hereditary angiodema (HAE) patients with normal C1 inhibitor (C1-INH) activity as among those with reduced or no C1-INH activity, according to real-world data from Brazilian patients. Most attacks were successfully treated with…
A new, highly sensitive genetic test that screens the entire SERPING1 gene is better than conventional genetic testing for diagnosing type 1 and type 2 hereditary angioedema, new research shows. Researchers now recommend this test as the first-line or as a confirmatory…
Subcutaneous Haegarda as a routine prevention for attacks of hereditary angioedema (HAE) significantly improves patients’ quality of life, such as lower anxiety levels and increased productivity at work, researchers found. The study, “Health-Related Quality-of-Life with Subcutaneous C1-inhibitor for Prevention of Attacks of Hereditary Angioedema,” was published…
Get regular updates to your inbox.
